Notably, CAR1 (CD8 TMD-CD3ζ SD) engineered NK cells demonstrated superior efficacy in treating tumor-bearing mice and showed enhanced persistence when combined with the OX40 CD. The gene discussed is CD8A; the disease is neoplasm.